LLY Eli Lilly and Co

By Sarah Coffey

Boehringer Ingelheim and Eli Lilly and Co. (LLY) said Monday their jointly-tested Type 1 diabetes drug achieved its primary endpoint in two controlled trials.

The companies said the EASE Phase III program investigated the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes during a 26-week trial.

The full results from the EASE Phase III program will be presented in October in Berlin.

Empagliflozin isn't currently approved for use in people with type 1 diabetes, which affects 1.3 million adults in the U.S. and approximately 30 million adults worldwide. Boehringer Ingelheim and Lilly said they are exploring regulatory options.

Write to Sarah Coffey at sarah.coffey@wsj.com

(END) Dow Jones Newswires

June 25, 2018 08:39 ET (12:39 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.